Publication details
Co nového u standardizovaného extraktu listů Ginkgo biloba EGb 761
| Title in English | What's new with standardised extract Ginkgo biloba leaf extract EGb 761 |
|---|---|
| Authors | |
| Year of publication | 2022 |
| Type | Article in Periodical |
| Magazine / Source | Praktické lékárenství |
| MU Faculty or unit | |
| Citation | |
| web | https://www.solen.cz/artkey/lek-202204-0009_co_noveho_u_standardizovaneho_extraktu_listu_ginkgo_biloba_egb_761.php?back=%2Fsearch.php%3Fquery%3DVilma%2BVranov%25E1%26sfrom%3D0%26spage%3D30 |
| Doi | http://dx.doi.org/10.36290/lek.2022.051 |
| Keywords | Ginkgo biloba; inflammation; cyclooxygenase; lipoxygenase |
| Description | Medicinal products containing ginseng extract belong to ATC group N06DX Other anti-dementia drugs. Their indications are dementia syndrome, occlusive disease of peripheral arteries, vertigo and tinnitus of a vascular or involutional nature. Currently, we understand more about the role of chronic systemic inflammation in the pathogenesis of many diseases, from atherosclerosis through diabetes mellitus II. type to Alzheimer's disease and other types of dementia. The focus of research on the effect of standardized of Ginkgo biloba leaf extract are the mechanisms of anti-inflammatory and neuroprotective effect. Anti-inflammatory effect of EGB 761 is mainly mediated by ginkgolides and bilobalides, which act as dual inhibitors of both cyclooxygenase and lipoxygenase. |